肺表面活性剂治疗21例新生儿呼吸窘迫综合征的临床观察

A clinical trial of the surfactant replacement therapy for neonatal respiratory distress syndrome

近几年，国内发达地区在治疗新生儿呼吸窘迫综合征（NRDS）时，应用肺表面活性制剂（PS），有较好的疗效。本院近两年也进行了该项治疗，现将PS治疗NRDS的疗效和安全性作一临床观察。

Objective To evaluate the efficacy and safety of pulmonary surfactant （PS） in the replacement therapy for neonatal respiratory distress syndrome （NRDS） Methods Twenty-one NRDS infants were treated with PS. The changes of lung function and lung aeration after the therapy and some common complications in premature infants were observed. Results Thirty minutes after the administration of PS, PaO2 significantly increased from 45 ± 13 mmHg to 96 ± 41mmHg, a / APO2 from 0.1 ± 0.04 to 0.26± 0.17, but PaO2 and a / APO2 remained on higher levels until seven days after the administration and were significantly different from the levels before the treatment （P 〈 0.01） After thirty minutes of the administration, PaCO2 decreased from 52± 15mmHg to 43±13mmHg （P 〈 0.01） After twelve hours of the administration, chest X-ray showed a significant improvement in lung aeration （P 〈 0.01） The incidences of the pneumothorax and pneumonia were 4.7% and 77%, respectively. Conclusion PS can rapidly and effectively improve the lung function and lung aeration in NRDS infants.